Related Experiment Video
Updated: Sep 10, 2025

A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Severe Group A Streptococcus Infection among Children, France, 2022-2024
Insights
Severe Group A Streptococcus infections in children increased in Europe. Treatments like corticosteroids and vasopressors were linked to worse outcomes, highlighting the need for public health collaboration.
Area of Science:
- Pediatrics
- Infectious Diseases
- Epidemiology
Background:
- Group A Streptococcus (GAS) infections have seen a notable increase in Europe since September 2022.
- Severe GAS infections in children require urgent clinical attention and epidemiological monitoring.
Purpose of the Study:
- To investigate the characteristics and outcomes of severe pediatric Group A Streptococcus infections.
- To identify risk factors associated with severe disease and mortality in children.
Main Methods:
- A retrospective and prospective study involving 402 pediatric patients across 34 French hospitals from September 1, 2022, to April 1, 2024.
- Analysis included clinical presentation, treatment interventions, molecular typing of GAS strains, and patient outcomes (sequelae or death).
Main Results:
- The majority of severe GAS cases involved respiratory tract infections (55%), with a lower proportion of skin and soft tissue infections (16%).
- The overall case-fatality rate was 3.5%. Hydrocortisone, corticosteroid, and vasopressor therapies were significantly associated with major sequelae or death.
- Emm1 (73.0%) and emm12 (10.8%) were the predominant emm types, with the M1UK clone accounting for 50% of emm1 strains.
Conclusions:
- Severe pediatric GAS infections present predominantly with respiratory symptoms and carry a significant risk of adverse outcomes.
- Specific therapeutic interventions, including corticosteroids and vasopressors, were associated with poorer prognoses, necessitating careful consideration in clinical management.
- Enhanced collaboration among clinicians, researchers, and public health authorities is crucial to effectively mitigate the impact of GAS on child health.
Abstract:
Group A Streptococcus infections have increased in Europe since September 2022. The French Pediatric Intensive Care and French Pediatric Infectious Diseases expert groups conducted a retrospective and prospective study of children who had severe group A Streptococcus infections during September 1, 2022-April 1, 2024, across 34 hospitals in France. A total of 402 pediatric patients (median age 4 [interquartile range 2-7.5] years; 42% girls, 58% boys) were enrolled. Cases were characterized by a low proportion of severe skin and soft tissue infections (16%), predominance of severe upper and lower respiratory tract infections (55%), and a 3.5% case-fatality rate. In multivariate analysis, hydrocortisone, corticosteroid, and vasopressor therapies were significantly associated with major sequelae or death. Molecular analysis revealed emm1 (73.0%) and emm12 (10.8%) strains; the M1UK clone represented 50% of emm1 strains. Clinicians, researchers, and public health authorities must collaborate to mitigate the effects of GAS on child health.
Related Concept Videos
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Tonsillitis I: Introduction
Etiology
Three primary contributing factors have been identified.
Tonsillitis II: Management
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Rheumatic Heart Disease I: Introduction

